Zhejiang East-Asia Pharmaceutical Co Ltd
605177
Company Profile
Business description
Zhejiang East-Asia Pharmaceutical Co Ltd is mainly engaged in the production of bulk pharmaceutical chemicals, tablets, granules and capsules. The company's main products are: Ofloxacin, levofloxacin, loratadine hydrochloride, levofloxacin hydrochloride, trimebutine maleate, ketoconazole, terbinafine hydrochloride, piperazine, ticlazole and so on.
Contact
No. 118, Laodong North Road
23rd Floor, Chamber of Commerce Building
Huangyan District
Zhejiang Province
Taizhou
CHNT: +86 57689185675
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,749
Stocks News & Analysis
stocks
Eli Lilly receives FDA approval to add another oral GLP-1 to market
Wide moat Eli Lilly receives FDA approval for obesity pill.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Which of the 3 giant AI IPOs should you buy?
OpenAI, Anthropic, and Databricks are expected to go public this year at massive valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,774.90 | 124.80 | -1.40% |
| CAC 40 | 7,981.27 | 164.33 | 2.10% |
| DAX 40 | 23,298.89 | 618.85 | 2.73% |
| Dow JONES (US) | 46,565.74 | 224.23 | 0.48% |
| FTSE 100 | 10,364.79 | 188.34 | 1.85% |
| HKSE | 24,908.84 | 385.19 | -1.52% |
| NASDAQ | 21,840.95 | 250.32 | 1.16% |
| Nikkei 225 | 52,418.44 | 1,321.24 | -2.46% |
| NZX 50 Index | 12,902.15 | 76.28 | 0.59% |
| S&P 500 | 6,575.32 | 46.80 | 0.72% |
| S&P/ASX 200 | 8,579.50 | 105.50 | -1.21% |
| SSE Composite Index | 3,913.97 | 34.58 | -0.88% |